VIMTALABS

Vimta Labs Share Price

₹961.90 -38.35 (-3.83%)

21 Dec, 2024 19:31

SIP TrendupStart SIP in VIMTALABS

Start SIP

Performance

  • Low
  • ₹951
  • High
  • ₹1,013
  • 52 Week Low
  • ₹390
  • 52 Week High
  • ₹1,070
  • Open Price₹1,000
  • Previous Close₹1,000
  • Volume125,339

Investment Returns

  • Over 1 Month + 29.56%
  • Over 3 Month + 70.66%
  • Over 6 Month + 92.88%
  • Over 1 Year + 145.38%
SIP Lightning

Smart Investing Starts Here Start SIP with Vimta Labs for Steady Growth!

Invest Now

Vimta Labs Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 42.7
  • PEG Ratio
  • 2.1
  • Market Cap Cr
  • 2,137
  • P/B Ratio
  • 6.7
  • Average True Range
  • 57.23
  • EPS
  • 24.04
  • Dividend Yield
  • 0.2
  • MACD Signal
  • 70.61
  • RSI
  • 64.96
  • MFI
  • 76.64

Vimta Labs Financials

Vimta Labs Technicals

EMA & SMA

Current Price
₹961.90
-38.35 (-3.83%)
pointer
  • stock-down_img
  • Bullish Moving Average 14
  • stock-up_img
  • Bearish Moving Average 2
  • 20 Day
  • ₹909.51
  • 50 Day
  • ₹792.59
  • 100 Day
  • ₹695.96
  • 200 Day
  • ₹611.95

Resistance and Support

975.22 Pivot Speed
  • R3 1,062.53
  • R2 1,037.87
  • R1 999.88
  • S1 937.23
  • S2 912.57
  • S3 874.58

What's your outlook on Vimta Labs?

You can only vote for once

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Vimta Labs Ltd. offers a wide range of testing, inspection, and analytical services, specializing in pharmaceuticals, food, and environmental testing. Serving clients globally, it provides high-quality, accredited lab services to ensure product safety and regulatory compliance.

Vimta Labs has an operating revenue of Rs. 327.86 Cr. on a trailing 12-month basis. An annual revenue de-growth of 0% needs improvement, Pre-tax margin of 17% is great, ROE of 12% is good. The company has a reasonable debt to equity of 3%, which signals a healthy balance sheet. The stock from a technical standpoint is comfortably placed above its key moving averages, around 36% and 75% from 50DMA and 200DMA. It has recently broken out of a base in its weekly chart and is trading around 42% from the pivot point (which is extended from the ideal buying range for a stock). From an O'Neil Methodology perspective, the stock has an EPS Rank of 89 which is a GOOD score indicating consistency in earnings, a RS Rating of 92 which is GREAT indicating the outperformance as compared to other stocks, Buyer Demand at A+ which is evident from recent demand for the stock, Group Rank of 34 indicates it belongs to a strong industry group of Medical-Services and a Master Score of B is close to being the best. Institutional holding has gone up in the last reported quarter is a positive sign. Overall, the stock has great fundamentals and technical strength to stay in momentum.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Vimta Labs Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2024-11-08 Quarterly Results
2024-07-17 Quarterly Results
2024-05-18 Audited Results & Final Dividend
2024-03-30 Amalgamation
2024-01-31 Quarterly Results
Date Purpose Remarks
2022-06-18 FINAL Rs.2.00 per share(100%)Dividend
2021-06-28 FINAL Rs.2.00 per share(100%)Dividend

Vimta Labs F&O

Vimta Labs Shareholding Pattern

36.89%
0%
3.31%
0%
26.53%
33.27%

About Vimta Labs

  • NSE Symbol
  • VIMTALABS
  • BSE Symbol
  • 524394
  • Managing Director
  • Ms. Harita Vasireddi
  • ISIN
  • INE579C01029

Similar Stocks to Vimta Labs

Vimta Labs FAQs

Vimta Labs share price is ₹961 As on 21 December, 2024 | 19:17

The Market Cap of Vimta Labs is ₹2136.7 Cr As on 21 December, 2024 | 19:17

The P/E ratio of Vimta Labs is 42.7 As on 21 December, 2024 | 19:17

The PB ratio of Vimta Labs is 6.7 As on 21 December, 2024 | 19:17

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23